Phase I clinical trial and pharmacokinetics of intravesical mitomycin C in dogs with localized transitional cell carcinoma of the urinary bladder

A. H. Abbo, D. R. Jones, A. R. Masters, J. C. Stewart, L. Fourez, D. W. Knapp

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: Transitional cell carcinoma (TCC) is the most common cancer of the urinary tract in dogs. The most frequent cause of death is urinary obstruction from the primary tumor. Standard medical therapy for TCC is only partially effective. Hypothesis/Objectives: Intravesical administration of mitomycin C (MMC) in dogs with invasive TCC will result in antitumor activity against the primary tumor and minimal systemic drug absorption. Animals: Thirteen privately owned dogs with naturally occurring, histopathologically diagnosed TCC of the urinary bladder. Methods: A prospective phase I trial was performed. MMC was given intravesically (600 mg/mL initial concentration) for 1 h/d for 2 consecutive days each month. The MMC concentration was escalated to a maximum of 800 mg/mL in groups of 3 dogs until the maximum tolerated dose (MTD) was determined. Serum assays for MMC were performed to determine the extent of systemic absorption of the MMC. Results: The MTD of MMC based on local toxicoses was 700 mg/mL (1-h dwell time, 2 consecutive days). In addition, 2 dogs had severe myelosuppression and appeared to have systemic absorption of MMC. Five dogs had partial remission, and 7 dogs had stable disease. Conclusions: IntravesicalMMChas antitumor activity in dogs with invasive TCC. Further study is needed to determine the cause of the myelosuppression associated with MMC administration, and to develop strategies to minimize this risk.

Original languageEnglish
Pages (from-to)1124-1130
Number of pages7
JournalJournal of veterinary internal medicine / American College of Veterinary Internal Medicine
Volume24
Issue number5
DOIs
StatePublished - Sep 2010

Fingerprint

mitomycin
Clinical Trials, Phase I
Transitional Cell Carcinoma
Mitomycin
bladder
pharmacokinetics
carcinoma
clinical trials
Urinary Bladder
Pharmacokinetics
Dogs
dogs
cells
Maximum Tolerated Dose
neoplasms
Urologic Neoplasms
Intravesical Administration
urinary tract
remission
dosage

Keywords

  • Bladder cancer
  • Canine species
  • Dog species

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Phase I clinical trial and pharmacokinetics of intravesical mitomycin C in dogs with localized transitional cell carcinoma of the urinary bladder. / Abbo, A. H.; Jones, D. R.; Masters, A. R.; Stewart, J. C.; Fourez, L.; Knapp, D. W.

In: Journal of veterinary internal medicine / American College of Veterinary Internal Medicine, Vol. 24, No. 5, 09.2010, p. 1124-1130.

Research output: Contribution to journalArticle

@article{dc087fb994584dc085ae47929f261e83,
title = "Phase I clinical trial and pharmacokinetics of intravesical mitomycin C in dogs with localized transitional cell carcinoma of the urinary bladder",
abstract = "Background: Transitional cell carcinoma (TCC) is the most common cancer of the urinary tract in dogs. The most frequent cause of death is urinary obstruction from the primary tumor. Standard medical therapy for TCC is only partially effective. Hypothesis/Objectives: Intravesical administration of mitomycin C (MMC) in dogs with invasive TCC will result in antitumor activity against the primary tumor and minimal systemic drug absorption. Animals: Thirteen privately owned dogs with naturally occurring, histopathologically diagnosed TCC of the urinary bladder. Methods: A prospective phase I trial was performed. MMC was given intravesically (600 mg/mL initial concentration) for 1 h/d for 2 consecutive days each month. The MMC concentration was escalated to a maximum of 800 mg/mL in groups of 3 dogs until the maximum tolerated dose (MTD) was determined. Serum assays for MMC were performed to determine the extent of systemic absorption of the MMC. Results: The MTD of MMC based on local toxicoses was 700 mg/mL (1-h dwell time, 2 consecutive days). In addition, 2 dogs had severe myelosuppression and appeared to have systemic absorption of MMC. Five dogs had partial remission, and 7 dogs had stable disease. Conclusions: IntravesicalMMChas antitumor activity in dogs with invasive TCC. Further study is needed to determine the cause of the myelosuppression associated with MMC administration, and to develop strategies to minimize this risk.",
keywords = "Bladder cancer, Canine species, Dog species",
author = "Abbo, {A. H.} and Jones, {D. R.} and Masters, {A. R.} and Stewart, {J. C.} and L. Fourez and Knapp, {D. W.}",
year = "2010",
month = "9",
doi = "10.1111/j.1939-1676.2010.0569.x",
language = "English",
volume = "24",
pages = "1124--1130",
journal = "Journal of Veterinary Internal Medicine",
issn = "0891-6640",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Phase I clinical trial and pharmacokinetics of intravesical mitomycin C in dogs with localized transitional cell carcinoma of the urinary bladder

AU - Abbo, A. H.

AU - Jones, D. R.

AU - Masters, A. R.

AU - Stewart, J. C.

AU - Fourez, L.

AU - Knapp, D. W.

PY - 2010/9

Y1 - 2010/9

N2 - Background: Transitional cell carcinoma (TCC) is the most common cancer of the urinary tract in dogs. The most frequent cause of death is urinary obstruction from the primary tumor. Standard medical therapy for TCC is only partially effective. Hypothesis/Objectives: Intravesical administration of mitomycin C (MMC) in dogs with invasive TCC will result in antitumor activity against the primary tumor and minimal systemic drug absorption. Animals: Thirteen privately owned dogs with naturally occurring, histopathologically diagnosed TCC of the urinary bladder. Methods: A prospective phase I trial was performed. MMC was given intravesically (600 mg/mL initial concentration) for 1 h/d for 2 consecutive days each month. The MMC concentration was escalated to a maximum of 800 mg/mL in groups of 3 dogs until the maximum tolerated dose (MTD) was determined. Serum assays for MMC were performed to determine the extent of systemic absorption of the MMC. Results: The MTD of MMC based on local toxicoses was 700 mg/mL (1-h dwell time, 2 consecutive days). In addition, 2 dogs had severe myelosuppression and appeared to have systemic absorption of MMC. Five dogs had partial remission, and 7 dogs had stable disease. Conclusions: IntravesicalMMChas antitumor activity in dogs with invasive TCC. Further study is needed to determine the cause of the myelosuppression associated with MMC administration, and to develop strategies to minimize this risk.

AB - Background: Transitional cell carcinoma (TCC) is the most common cancer of the urinary tract in dogs. The most frequent cause of death is urinary obstruction from the primary tumor. Standard medical therapy for TCC is only partially effective. Hypothesis/Objectives: Intravesical administration of mitomycin C (MMC) in dogs with invasive TCC will result in antitumor activity against the primary tumor and minimal systemic drug absorption. Animals: Thirteen privately owned dogs with naturally occurring, histopathologically diagnosed TCC of the urinary bladder. Methods: A prospective phase I trial was performed. MMC was given intravesically (600 mg/mL initial concentration) for 1 h/d for 2 consecutive days each month. The MMC concentration was escalated to a maximum of 800 mg/mL in groups of 3 dogs until the maximum tolerated dose (MTD) was determined. Serum assays for MMC were performed to determine the extent of systemic absorption of the MMC. Results: The MTD of MMC based on local toxicoses was 700 mg/mL (1-h dwell time, 2 consecutive days). In addition, 2 dogs had severe myelosuppression and appeared to have systemic absorption of MMC. Five dogs had partial remission, and 7 dogs had stable disease. Conclusions: IntravesicalMMChas antitumor activity in dogs with invasive TCC. Further study is needed to determine the cause of the myelosuppression associated with MMC administration, and to develop strategies to minimize this risk.

KW - Bladder cancer

KW - Canine species

KW - Dog species

UR - http://www.scopus.com/inward/record.url?scp=77957897981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957897981&partnerID=8YFLogxK

U2 - 10.1111/j.1939-1676.2010.0569.x

DO - 10.1111/j.1939-1676.2010.0569.x

M3 - Article

C2 - 20695986

AN - SCOPUS:77957897981

VL - 24

SP - 1124

EP - 1130

JO - Journal of Veterinary Internal Medicine

JF - Journal of Veterinary Internal Medicine

SN - 0891-6640

IS - 5

ER -